FocalTherics Reports Preliminary Q2 Sales Of $12.7M-$13.2M, Up 34%-39% Year-On-Year
During the second quarter of 2026, the Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements —
FocalTherics sold between $12.7 million and $13.2 million in the second quarter, which is about one-third more than last year at this time. When a company grows its sales like this, it suggests customers want what they're making, which is a sign to watch.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.